Acadia kept at market outperform by JMP

JMP Securities analyst Charles C. Duncan reiterated Acadia Pharmaceuticals Inc. at its market outperform rating and $18 price target. The company's third-quarter financial results were below expectations on the top line but beat expectations on the bottom line. The analyst lowered 2006 revenues to $8.5 million, from $9.8 million, and increased Acadia's projected net loss to $1.73 per share from $1.65 per share. Shares of the San Diego biopharmaceutical company were down 47 cents, or 4.52%, at $9.93. (Nasdaq: ACAD)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.